England’s antibiotic use climbs again after years of pandemic-era contraction
England’s monthly antibiotic consumption moved higher through 2024 and into 2025, reversing part of the steep drop that followed the first phase of the COVID-19 era. Total antibiotic use, measured as defined daily doses per 1,000 inhabitants per day, ended December 2025 at 17.73 DID, up from 16.96 in November 2024 and far above the pandemic trough of 14.69 in April 2021. Primary care showed the same broad shape, finishing December 2025 at 13.38 DID after rising from 13.08 in November 2024 and bottoming out at 11.64 in April 2021.
The pattern is clinically meaningful because antibiotic consumption is one of the clearest population-level proxies for prescriber behavior, diagnostic uncertainty, and the circulating burden of infections that trigger treatment. When use falls abruptly, the signal often reflects reduced face-to-face care, fewer respiratory consultations, or tighter stewardship. When it rises again, clinicians usually see a return of everyday prescribing pressure: sore throats, cough, urinary symptoms, skin infections, and the persistent demand to treat when viral illness remains more likely than bacterial disease.
Between the end of 2018 and early 2020, the baseline hardly moved. Total use slipped from 18.27 DID in December 2018 to 18.13 DID in February 2020, while primary care edged from 14.57 to 14.46 DID over the same period. The real inflection arrived in spring 2020, when total use fell from 18.49 DID in March 2020 to 14.69 DID in April 2021. Primary care dropped in parallel, from 14.82 DID in March 2020 to 11.64 DID in April 2021.
Primary care remains the main driver of national antibiotic pressure
The primary care curve matters because most community antibiotic exposure begins there. General practice and urgent care are where respiratory syndromes, uncomplicated urinary symptoms, and minor soft-tissue infections most often meet prescribing decisions, and where the line between symptom relief and unnecessary antimicrobial exposure is drawn every day. In the England data, primary care accounted for the larger share of the overall change, falling faster than the total series during the initial pandemic decline and then recovering more slowly.
From May 2021, primary care use started climbing again, rising from 11.07 DID to 12.80 DID by June 2022. After that rebound, a quieter phase followed: the series slipped from 12.47 DID in July 2022 to 12.13 DID in August 2023. The next leg upward began in autumn 2023, with primary care moving from 12.27 DID in September 2023 to 12.88 DID in October 2024, before the latest increase to 13.38 DID in December 2025.
Total antibiotic use followed the same broad sequence but with a slightly higher absolute level at every checkpoint. After the sharp decline through April 2021, total use rose from 14.0 DID in May 2021 to 16.23 DID in June 2022. It then eased from 15.79 DID in July 2022 to 15.71 DID in August 2023, before climbing again from 15.73 DID in September 2023 to 16.9 DID in October 2024 and 17.73 DID in December 2025.
A rise of this kind does not automatically imply inappropriate prescribing. Bacterial infections still require treatment, and delayed or withheld therapy can be harmful when sepsis, pneumonia, pyelonephritis, or invasive skin infection are in play. But sustained population-wide increases in exposure also widen the ecological space for resistance selection, especially when broad-spectrum agents are used where a narrower drug, or no antibiotic at all, would have been enough.
Stewardship pressure returns as prescribing volumes edge upward
Antibiotic consumption sits at the center of antimicrobial resistance policy because every additional course exerts selection pressure on commensal and pathogenic bacteria alike. Repeated exposure encourages resistant organisms to survive and spread, and the consequences reach well beyond the treated patient: more difficult future infections, fewer oral options, longer hospital stays, and greater dependence on broader-spectrum agents. The practical danger is cumulative rather than immediate. Small monthly increases, repeated over time across a large population, change the microbial background against which clinicians practice.
The England series also suggests that post-pandemic prescribing has not returned to a single stable plateau. Instead, it has fluctuated in phases: an early baseline, a sharp contraction, a rebound, a short plateau, and then another climb late in the period. In real-world stewardship terms, that means the system is still absorbing shifts in access, consultation volume, symptom burden, and prescribing habit. A monthly rise of a few tenths of a DID may look modest in isolation, yet on a national scale it represents a substantial amount of additional antimicrobial exposure.
The data carry one more bedside implication. When community antibiotic use rises, clinicians need to remain alert to diagnostic discipline: distinguishing viral from bacterial illness, using rapid tests where appropriate, and reserving antibiotics for cases with a clear microbiologic or clinical justification. That discipline is especially important in primary care, where the first prescription often sets the tone for future patient expectations.
The chart ends with both measures higher in December 2025 than they were a year earlier, and neither series has returned to its pre-pandemic baseline. The remaining question is not whether antibiotic use can be reduced further, but how much of the late rebound reflects changing infection patterns, how much reflects prescribing behavior, and how quickly stewardship gains can be rebuilt without compromising timely treatment for patients who truly need antimicrobials.